FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 308:1393-1395 June 9, 1983 Number 23 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We gave danazol (600 mg per day orally for 14 days), an attenuated androgen, to four adults with classic hemophilia and one adult with Christmas disease. The levels of factor VIII in the patients with classic hemophilia ranged from 1 to 3 per cent before treatment and rose to 3 to 8 per cent during the treatment period. The level of factor IX in the patient with Christmas disease rose from 5 to 14 per cent. The rise in clotting-factor activity was usually observed within five to six days after the initiation of therapy and peaked between 7 and 13 days. The drug had no untoward effects. During the 70 patient-days of therapy, only two patients required plasma products, each on one occasion. These data suggest that danazol therapy may decrease the hemorrhagic tendency and reduce the need for transfusions of plasma products in classic hemophilia and Christmas disease. Controlled clinical trials will be required to establish its value in these applications.

This article has been cited by other articles:

• BRIET, E., WIJNANDS, M. C., VELTKAMP, J. J. (1985). The Prophylactic Treatment of Hemophilia B Leyden with Anabolic Steroids. ANN INTERN MED 103: 225-226 [Abstract]  
• CINES, D. B., CASSILETH, P. A, KISS, J. E. (1985). Danazol Therapy in Myelodysplasia. ANN INTERN MED 103: 58-60 [Abstract]  
• Gralnick, H. R., Maisonneuve, P., Sultan, Y., Rick, M. E. (1985). Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia). JAMA 253: 1151-1153 [Abstract]  
• Garewal, H. S., Corrigan, J. J. Jr, Durie, B. G. M., Jeter, M. A., Damiano, M. L. (1985). Effect of Danazol on Coagulation Parameters and Bleeding in Hemophilia. JAMA 253: 1154-1156 [Abstract]  
• Hathaway, W. E. (1985). Danazol and Hemophilia. JAMA 253: 1167-1167 [Abstract]  
• METROKA, C. E., MOORE, A., SONNABEND, J. A., CUNNINGHAM-RUNDLES, S. (1984). Risks with Danazol in the Acquired Immunodeficiency Syndrome. ANN INTERN MED 101: 564-565 [Abstract]